0001104659-22-086060.txt : 20220902 0001104659-22-086060.hdr.sgml : 20220902 20220804143808 ACCESSION NUMBER: 0001104659-22-086060 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20220804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Quoin Pharmaceuticals, Ltd. CENTRAL INDEX KEY: 0001671502 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 23 HATA'AS STREET CITY: KFAR SABA STATE: L3 ZIP: 44425 BUSINESS PHONE: 97299741444 MAIL ADDRESS: STREET 1: 23 HATA'AS STREET CITY: KFAR SABA STATE: L3 ZIP: 44425 FORMER COMPANY: FORMER CONFORMED NAME: Cellect Biotechnology Ltd. DATE OF NAME CHANGE: 20160721 FORMER COMPANY: FORMER CONFORMED NAME: Cellect Biomed Ltd. DATE OF NAME CHANGE: 20160406 CORRESP 1 filename1.htm

Quoin Pharmaceuticals Ltd.

Azrieli Center, Round Tower, 30th Floor

132 Menachem Begin Blvd

Tel Aviv, 6701101

August 4, 2022

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn: Christine Westbrook

RE:

Quoin Pharmaceuticals Ltd.
Registration Statement on Form F-1
Registration No. 333-266476

Ladies and Gentlemen:

Quoin Pharmaceuticals Ltd. (the “Company”) hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of the effective date of the above-referenced Registration Statement, as amended, so that such Registration Statement, as amended, will become effective at 9:00 a.m., Eastern Time, on Friday, August 5, 2022, or as soon thereafter as practicable.

[Signature Page Follows]

	Very truly yours,

	QUOIN PHARMACEUTICALS LTD.


	By:	/s/ Dr. Michael Myers
		Name: Dr. Michael Myers
		Title: Chief Executive Officer